PCRX logo

Pacira BioSciences (PCRX) Free Cash Flow

Annual FCF

$139.49 M
+$24.29 M+21.09%

December 31, 2023


Summary


Performance

PCRX Free Cash Flow Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherPCRXcash flowmetrics:

Quarterly FCF

$49.83 M
-$1.82 M-3.52%

September 30, 2024


Summary


Performance

PCRX Quarterly FCF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherPCRXcash flowmetrics:

TTM FCF

$193.53 M
+$8.78 M+4.75%

September 30, 2024


Summary


Performance

PCRX TTM FCF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherPCRXcash flowmetrics:

Free Cash Flow Formula

FCF = Cash From Operations − CAPEX

PCRX Free Cash Flow Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+21.1%+21.4%+48.6%
3 y3 years+255.6%+115.6%+86.2%
5 y5 years+306.0%+115.6%+86.2%

PCRX Free Cash Flow Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+74.7%-3.5%+296.6%at high+142.4%
5 y5-yearat high+255.6%-3.5%+303.1%at high+1374.7%
alltimeall timeat high+257.8%-3.5%+292.3%at high+318.9%

Pacira BioSciences Free Cash Flow History

DateAnnualQuarterlyTTM
Sep 2024
-
$49.83 M(-3.5%)
$193.53 M(+4.8%)
Jun 2024
-
$51.65 M(+11.6%)
$184.74 M(+6.7%)
Mar 2024
-
$46.27 M(+1.0%)
$173.19 M(+24.2%)
Dec 2023
$139.49 M(+21.1%)
$45.79 M(+11.6%)
$139.49 M(+7.1%)
Sep 2023
-
$41.04 M(+2.4%)
$130.25 M(+2.8%)
Jun 2023
-
$40.09 M(+219.2%)
$126.68 M(+21.0%)
Mar 2023
-
$12.56 M(-65.6%)
$104.65 M(-9.2%)
Dec 2022
$115.20 M(+44.3%)
$36.55 M(-2.5%)
$115.20 M(+24.3%)
Sep 2022
-
$37.47 M(+107.4%)
$92.70 M(-9.5%)
Jun 2022
-
$18.07 M(-21.8%)
$102.44 M(-1.5%)
Mar 2022
-
$23.11 M(+64.5%)
$103.95 M(+30.2%)
Dec 2021
$79.85 M(+103.5%)
$14.05 M(-70.2%)
$79.85 M(-18.6%)
Sep 2021
-
$47.21 M(+141.1%)
$98.06 M(+18.3%)
Jun 2021
-
$19.58 M(-2074.1%)
$82.87 M(+113.8%)
Mar 2021
-
-$992.00 K(-103.1%)
$38.76 M(-1.2%)
Dec 2020
$39.23 M(-35.0%)
$32.26 M(+0.8%)
$39.23 M(+38.2%)
Sep 2020
-
$32.02 M(-230.5%)
$28.38 M(+116.3%)
Jun 2020
-
-$24.53 M(+4653.9%)
$13.12 M(-77.5%)
Mar 2020
-
-$516.00 K(-102.4%)
$58.36 M(-3.3%)
Dec 2019
$60.36 M(+75.7%)
$21.41 M(+27.7%)
$60.36 M(+4.2%)
Sep 2019
-
$16.76 M(-19.1%)
$57.93 M(+8.6%)
Jun 2019
-
$20.71 M(+1298.4%)
$53.34 M(+22.0%)
Mar 2019
-
$1.48 M(-92.2%)
$43.71 M(+27.2%)
Dec 2018
$34.36 M(-2419.8%)
$18.98 M(+55.9%)
$34.36 M(+26.2%)
Sep 2018
-
$12.18 M(+9.9%)
$27.23 M(+298.7%)
Jun 2018
-
$11.08 M(-240.7%)
$6.83 M(-218.9%)
Mar 2018
-
-$7.87 M(-166.4%)
-$5.74 M(+287.8%)
Dec 2017
-$1.48 M
$11.86 M(-244.1%)
-$1.48 M(+70.4%)
Sep 2017
-
-$8.23 M(+448.8%)
-$869.00 K(-105.7%)
Jun 2017
-
-$1.50 M(-58.5%)
$15.14 M(-1.1%)
DateAnnualQuarterlyTTM
Mar 2017
-
-$3.61 M(-129.0%)
$15.31 M(+75.1%)
Dec 2016
$8.74 M(-171.2%)
$12.47 M(+60.3%)
$8.74 M(+108.8%)
Sep 2016
-
$7.78 M(-686.1%)
$4.19 M(-140.4%)
Jun 2016
-
-$1.33 M(-87.0%)
-$10.38 M(-24.3%)
Mar 2016
-
-$10.17 M(-228.6%)
-$13.70 M(+11.7%)
Dec 2015
-$12.27 M(-442.8%)
$7.91 M(-216.6%)
-$12.27 M(-14.1%)
Sep 2015
-
-$6.79 M(+45.8%)
-$14.29 M(+311.8%)
Jun 2015
-
-$4.65 M(-46.8%)
-$3.47 M(-202.6%)
Mar 2015
-
-$8.74 M(-248.2%)
$3.38 M(-5.6%)
Dec 2014
$3.58 M(-106.4%)
$5.90 M(+46.4%)
$3.58 M(-129.8%)
Sep 2014
-
$4.03 M(+83.6%)
-$12.03 M(-60.7%)
Jun 2014
-
$2.19 M(-125.7%)
-$30.59 M(-36.1%)
Mar 2014
-
-$8.54 M(-12.0%)
-$47.83 M(-14.6%)
Dec 2013
-$56.01 M(-36.6%)
-$9.71 M(-33.2%)
-$56.01 M(-22.4%)
Sep 2013
-
-$14.53 M(-3.4%)
-$72.22 M(-3.9%)
Jun 2013
-
-$15.05 M(-10.0%)
-$75.12 M(-11.3%)
Mar 2013
-
-$16.72 M(-35.5%)
-$84.66 M(-4.2%)
Dec 2012
-$88.39 M(+137.8%)
-$25.91 M(+48.6%)
-$88.39 M(+21.8%)
Sep 2012
-
-$17.43 M(-29.1%)
-$72.56 M(+11.2%)
Jun 2012
-
-$24.59 M(+20.3%)
-$65.26 M(+23.6%)
Mar 2012
-
-$20.45 M(+102.9%)
-$52.79 M(+42.0%)
Dec 2011
-$37.17 M(+17.4%)
-$10.08 M(-0.6%)
-$37.17 M(+3.6%)
Sep 2011
-
-$10.14 M(-16.4%)
-$35.88 M(+3.9%)
Jun 2011
-
-$12.13 M(+151.6%)
-$34.55 M(+6.4%)
Mar 2011
-
-$4.82 M(-45.2%)
-$32.46 M(+2.5%)
Dec 2010
-$31.65 M(+20.1%)
-$8.79 M(-0.3%)
-$31.65 M(+38.4%)
Sep 2010
-
-$8.81 M(-12.2%)
-$22.86 M(+62.7%)
Jun 2010
-
-$10.04 M(+150.1%)
-$14.05 M(+250.1%)
Mar 2010
-
-$4.01 M
-$4.01 M
Dec 2009
-$26.35 M(-24.8%)
-
-
Dec 2008
-$35.03 M
-
-

FAQ

  • What is Pacira BioSciences annual free cash flow?
  • What is the all time high annual FCF for Pacira BioSciences?
  • What is Pacira BioSciences annual FCF year-on-year change?
  • What is Pacira BioSciences quarterly free cash flow?
  • What is the all time high quarterly FCF for Pacira BioSciences?
  • What is Pacira BioSciences quarterly FCF year-on-year change?
  • What is Pacira BioSciences TTM free cash flow?
  • What is the all time high TTM FCF for Pacira BioSciences?
  • What is Pacira BioSciences TTM FCF year-on-year change?

What is Pacira BioSciences annual free cash flow?

The current annual FCF of PCRX is $139.49 M

What is the all time high annual FCF for Pacira BioSciences?

Pacira BioSciences all-time high annual free cash flow is $139.49 M

What is Pacira BioSciences annual FCF year-on-year change?

Over the past year, PCRX annual free cash flow has changed by +$24.29 M (+21.09%)

What is Pacira BioSciences quarterly free cash flow?

The current quarterly FCF of PCRX is $49.83 M

What is the all time high quarterly FCF for Pacira BioSciences?

Pacira BioSciences all-time high quarterly free cash flow is $51.65 M

What is Pacira BioSciences quarterly FCF year-on-year change?

Over the past year, PCRX quarterly free cash flow has changed by +$8.78 M (+21.40%)

What is Pacira BioSciences TTM free cash flow?

The current TTM FCF of PCRX is $193.53 M

What is the all time high TTM FCF for Pacira BioSciences?

Pacira BioSciences all-time high TTM free cash flow is $193.53 M

What is Pacira BioSciences TTM FCF year-on-year change?

Over the past year, PCRX TTM free cash flow has changed by +$63.28 M (+48.58%)